nodes	percent_of_prediction	percent_of_DWPC	metapath
Pramipexole—SLC22A2—Cladribine—multiple sclerosis	0.146	0.535	CbGbCtD
Pramipexole—SLC22A1—Cladribine—multiple sclerosis	0.127	0.465	CbGbCtD
Pramipexole—HTR1B—trigeminal nucleus—multiple sclerosis	0.036	0.173	CbGeAlD
Pramipexole—HTR1D—trigeminal nucleus—multiple sclerosis	0.0348	0.167	CbGeAlD
Pramipexole—HTR1D—meninx—multiple sclerosis	0.0231	0.111	CbGeAlD
Pramipexole—HTR2A—trigeminal nucleus—multiple sclerosis	0.0173	0.083	CbGeAlD
Pramipexole—HTR1B—trigeminal nerve—multiple sclerosis	0.00945	0.0453	CbGeAlD
Pramipexole—HTR1D—trigeminal nerve—multiple sclerosis	0.00915	0.0439	CbGeAlD
Pramipexole—HTR2A—trigeminal nerve—multiple sclerosis	0.00454	0.0218	CbGeAlD
Pramipexole—DRD1—nerve—multiple sclerosis	0.00426	0.0204	CbGeAlD
Pramipexole—HTR2A—pons—multiple sclerosis	0.0032	0.0153	CbGeAlD
Pramipexole—DRD2—nerve—multiple sclerosis	0.00252	0.0121	CbGeAlD
Pramipexole—ADRA2A—peripheral nervous system—multiple sclerosis	0.0025	0.012	CbGeAlD
Pramipexole—HTR2A—pineal body—multiple sclerosis	0.00228	0.011	CbGeAlD
Pramipexole—HTR2A—peripheral nervous system—multiple sclerosis	0.00213	0.0102	CbGeAlD
Pramipexole—DRD1—brainstem—multiple sclerosis	0.00183	0.00877	CbGeAlD
Pramipexole—HTR2A—nerve—multiple sclerosis	0.00166	0.00796	CbGeAlD
Pramipexole—HTR1B—brainstem—multiple sclerosis	0.00148	0.00711	CbGeAlD
Pramipexole—DRD4—brain—multiple sclerosis	0.00145	0.00698	CbGeAlD
Pramipexole—HTR1D—brainstem—multiple sclerosis	0.00143	0.00688	CbGeAlD
Pramipexole—HTR2C—brainstem—multiple sclerosis	0.00142	0.00681	CbGeAlD
Pramipexole—DRD3—nervous system—multiple sclerosis	0.00134	0.00642	CbGeAlD
Pramipexole—DRD3—central nervous system—multiple sclerosis	0.00129	0.00618	CbGeAlD
Pramipexole—DRD5—nervous system—multiple sclerosis	0.00125	0.00601	CbGeAlD
Pramipexole—DRD5—central nervous system—multiple sclerosis	0.00121	0.00579	CbGeAlD
Pramipexole—HTR1A—brainstem—multiple sclerosis	0.0012	0.00573	CbGeAlD
Pramipexole—DRD1—midbrain—multiple sclerosis	0.00116	0.00559	CbGeAlD
Pramipexole—DRD2—brainstem—multiple sclerosis	0.00108	0.00518	CbGeAlD
Pramipexole—DRD2—retina—multiple sclerosis	0.00104	0.005	CbGeAlD
Pramipexole—DRD3—brain—multiple sclerosis	0.00102	0.0049	CbGeAlD
Pramipexole—HTR2C—medulla oblongata—multiple sclerosis	0.00099	0.00475	CbGeAlD
Pramipexole—DRD5—brain—multiple sclerosis	0.000958	0.0046	CbGeAlD
Pramipexole—DRD1—nervous system—multiple sclerosis	0.000958	0.00459	CbGeAlD
Pramipexole—HTR1B—midbrain—multiple sclerosis	0.000944	0.00453	CbGeAlD
Pramipexole—DRD1—central nervous system—multiple sclerosis	0.000922	0.00442	CbGeAlD
Pramipexole—HTR1B—spinal cord—multiple sclerosis	0.000921	0.00442	CbGeAlD
Pramipexole—HTR1D—midbrain—multiple sclerosis	0.000914	0.00438	CbGeAlD
Pramipexole—HTR2C—midbrain—multiple sclerosis	0.000905	0.00434	CbGeAlD
Pramipexole—HTR2C—spinal cord—multiple sclerosis	0.000883	0.00424	CbGeAlD
Pramipexole—HTR1B—nervous system—multiple sclerosis	0.000776	0.00372	CbGeAlD
Pramipexole—HTR1A—midbrain—multiple sclerosis	0.000762	0.00365	CbGeAlD
Pramipexole—SLC22A1—nervous system—multiple sclerosis	0.000758	0.00364	CbGeAlD
Pramipexole—HTR1D—nervous system—multiple sclerosis	0.000751	0.0036	CbGeAlD
Pramipexole—HTR1B—central nervous system—multiple sclerosis	0.000747	0.00358	CbGeAlD
Pramipexole—HTR2C—nervous system—multiple sclerosis	0.000744	0.00357	CbGeAlD
Pramipexole—HTR1A—spinal cord—multiple sclerosis	0.000743	0.00357	CbGeAlD
Pramipexole—ADRA2C—medulla oblongata—multiple sclerosis	0.000732	0.00351	CbGeAlD
Pramipexole—DRD1—brain—multiple sclerosis	0.000732	0.00351	CbGeAlD
Pramipexole—SLC22A1—central nervous system—multiple sclerosis	0.00073	0.0035	CbGeAlD
Pramipexole—HTR1D—central nervous system—multiple sclerosis	0.000723	0.00347	CbGeAlD
Pramipexole—HTR2C—central nervous system—multiple sclerosis	0.000716	0.00344	CbGeAlD
Pramipexole—HTR2A—brainstem—multiple sclerosis	0.000712	0.00342	CbGeAlD
Pramipexole—HTR2B—nervous system—multiple sclerosis	0.000699	0.00335	CbGeAlD
Pramipexole—DRD2—midbrain—multiple sclerosis	0.000688	0.0033	CbGeAlD
Pramipexole—HTR2A—retina—multiple sclerosis	0.000687	0.0033	CbGeAlD
Pramipexole—HTR2B—central nervous system—multiple sclerosis	0.000673	0.00323	CbGeAlD
Pramipexole—ADRA2C—midbrain—multiple sclerosis	0.000669	0.00321	CbGeAlD
Pramipexole—ADRA2C—spinal cord—multiple sclerosis	0.000653	0.00313	CbGeAlD
Pramipexole—HTR1A—nervous system—multiple sclerosis	0.000626	0.003	CbGeAlD
Pramipexole—HTR1A—central nervous system—multiple sclerosis	0.000603	0.00289	CbGeAlD
Pramipexole—HTR1B—brain—multiple sclerosis	0.000593	0.00285	CbGeAlD
Pramipexole—HTR1A—cerebellum—multiple sclerosis	0.000589	0.00283	CbGeAlD
Pramipexole—ADRA2A—medulla oblongata—multiple sclerosis	0.000584	0.0028	CbGeAlD
Pramipexole—SLC22A1—brain—multiple sclerosis	0.000579	0.00278	CbGeAlD
Pramipexole—HTR1D—brain—multiple sclerosis	0.000574	0.00275	CbGeAlD
Pramipexole—HTR2C—brain—multiple sclerosis	0.000569	0.00273	CbGeAlD
Pramipexole—DRD2—nervous system—multiple sclerosis	0.000566	0.00271	CbGeAlD
Pramipexole—ADRA2C—nervous system—multiple sclerosis	0.00055	0.00264	CbGeAlD
Pramipexole—DRD2—central nervous system—multiple sclerosis	0.000545	0.00261	CbGeAlD
Pramipexole—HTR2B—brain—multiple sclerosis	0.000534	0.00256	CbGeAlD
Pramipexole—ADRA2A—midbrain—multiple sclerosis	0.000534	0.00256	CbGeAlD
Pramipexole—DRD2—cerebellum—multiple sclerosis	0.000532	0.00255	CbGeAlD
Pramipexole—ADRA2C—central nervous system—multiple sclerosis	0.00053	0.00254	CbGeAlD
Pramipexole—ADRA2A—spinal cord—multiple sclerosis	0.000521	0.0025	CbGeAlD
Pramipexole—ADRA2C—cerebellum—multiple sclerosis	0.000518	0.00248	CbGeAlD
Pramipexole—HTR2A—medulla oblongata—multiple sclerosis	0.000497	0.00238	CbGeAlD
Pramipexole—HTR1A—brain—multiple sclerosis	0.000479	0.0023	CbGeAlD
Pramipexole—HTR2A—midbrain—multiple sclerosis	0.000454	0.00218	CbGeAlD
Pramipexole—HTR2A—spinal cord—multiple sclerosis	0.000443	0.00212	CbGeAlD
Pramipexole—ADRA2A—nervous system—multiple sclerosis	0.000439	0.00211	CbGeAlD
Pramipexole—DRD2—brain—multiple sclerosis	0.000432	0.00207	CbGeAlD
Pramipexole—ADRA2A—central nervous system—multiple sclerosis	0.000423	0.00203	CbGeAlD
Pramipexole—ADRA2C—brain—multiple sclerosis	0.00042	0.00202	CbGeAlD
Pramipexole—ADRA2A—cerebellum—multiple sclerosis	0.000413	0.00198	CbGeAlD
Pramipexole—HTR2A—nervous system—multiple sclerosis	0.000373	0.00179	CbGeAlD
Pramipexole—HTR2A—central nervous system—multiple sclerosis	0.000359	0.00172	CbGeAlD
Pramipexole—HTR2A—cerebellum—multiple sclerosis	0.000351	0.00168	CbGeAlD
Pramipexole—ADRA2A—brain—multiple sclerosis	0.000335	0.00161	CbGeAlD
Pramipexole—HTR2A—brain—multiple sclerosis	0.000285	0.00137	CbGeAlD
Pramipexole—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000127	0.000339	CcSEcCtD
Pramipexole—Loss of consciousness—Betamethasone—multiple sclerosis	0.000127	0.000338	CcSEcCtD
Pramipexole—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000127	0.000338	CcSEcCtD
Pramipexole—Epistaxis—Methotrexate—multiple sclerosis	0.000127	0.000338	CcSEcCtD
Pramipexole—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000127	0.000338	CcSEcCtD
Pramipexole—Paraesthesia—Prednisolone—multiple sclerosis	0.000127	0.000338	CcSEcCtD
Pramipexole—Tachycardia—Triamcinolone—multiple sclerosis	0.000127	0.000338	CcSEcCtD
Pramipexole—Mental disorder—Prednisone—multiple sclerosis	0.000126	0.000337	CcSEcCtD
Pramipexole—Nausea—Azathioprine—multiple sclerosis	0.000126	0.000337	CcSEcCtD
Pramipexole—Tachycardia—Methylprednisolone—multiple sclerosis	0.000126	0.000337	CcSEcCtD
Pramipexole—Skin disorder—Methylprednisolone—multiple sclerosis	0.000126	0.000335	CcSEcCtD
Pramipexole—Malnutrition—Prednisone—multiple sclerosis	0.000126	0.000335	CcSEcCtD
Pramipexole—Erythema—Prednisone—multiple sclerosis	0.000126	0.000335	CcSEcCtD
Pramipexole—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000125	0.000335	CcSEcCtD
Pramipexole—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000125	0.000334	CcSEcCtD
Pramipexole—Convulsion—Dexamethasone—multiple sclerosis	0.000125	0.000333	CcSEcCtD
Pramipexole—Convulsion—Betamethasone—multiple sclerosis	0.000125	0.000333	CcSEcCtD
Pramipexole—Hypertension—Betamethasone—multiple sclerosis	0.000125	0.000332	CcSEcCtD
Pramipexole—Hypertension—Dexamethasone—multiple sclerosis	0.000125	0.000332	CcSEcCtD
Pramipexole—Asthenia—Mitoxantrone—multiple sclerosis	0.000123	0.000329	CcSEcCtD
Pramipexole—Myalgia—Dexamethasone—multiple sclerosis	0.000123	0.000328	CcSEcCtD
Pramipexole—Myalgia—Betamethasone—multiple sclerosis	0.000123	0.000328	CcSEcCtD
Pramipexole—Anxiety—Betamethasone—multiple sclerosis	0.000122	0.000326	CcSEcCtD
Pramipexole—Anxiety—Dexamethasone—multiple sclerosis	0.000122	0.000326	CcSEcCtD
Pramipexole—Discomfort—Betamethasone—multiple sclerosis	0.000121	0.000324	CcSEcCtD
Pramipexole—Discomfort—Dexamethasone—multiple sclerosis	0.000121	0.000324	CcSEcCtD
Pramipexole—Hypotension—Methylprednisolone—multiple sclerosis	0.000121	0.000323	CcSEcCtD
Pramipexole—Pain—Prednisolone—multiple sclerosis	0.000121	0.000322	CcSEcCtD
Pramipexole—Pharyngitis—Methotrexate—multiple sclerosis	0.00012	0.000319	CcSEcCtD
Pramipexole—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000119	0.000318	CcSEcCtD
Pramipexole—Vision blurred—Prednisone—multiple sclerosis	0.000118	0.000316	CcSEcCtD
Pramipexole—Urethral disorder—Methotrexate—multiple sclerosis	0.000118	0.000315	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000118	0.000315	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000118	0.000315	CcSEcCtD
Pramipexole—Oedema—Betamethasone—multiple sclerosis	0.000118	0.000314	CcSEcCtD
Pramipexole—Oedema—Dexamethasone—multiple sclerosis	0.000118	0.000314	CcSEcCtD
Pramipexole—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000118	0.000314	CcSEcCtD
Pramipexole—Insomnia—Triamcinolone—multiple sclerosis	0.000117	0.000313	CcSEcCtD
Pramipexole—Insomnia—Methylprednisolone—multiple sclerosis	0.000117	0.000312	CcSEcCtD
Pramipexole—Infection—Betamethasone—multiple sclerosis	0.000117	0.000312	CcSEcCtD
Pramipexole—Infection—Dexamethasone—multiple sclerosis	0.000117	0.000312	CcSEcCtD
Pramipexole—Ill-defined disorder—Prednisone—multiple sclerosis	0.000117	0.000311	CcSEcCtD
Pramipexole—Paraesthesia—Triamcinolone—multiple sclerosis	0.000117	0.000311	CcSEcCtD
Pramipexole—Feeling abnormal—Prednisolone—multiple sclerosis	0.000116	0.00031	CcSEcCtD
Pramipexole—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000116	0.00031	CcSEcCtD
Pramipexole—Visual impairment—Methotrexate—multiple sclerosis	0.000116	0.00031	CcSEcCtD
Pramipexole—Anaemia—Prednisone—multiple sclerosis	0.000116	0.00031	CcSEcCtD
Pramipexole—Shock—Dexamethasone—multiple sclerosis	0.000116	0.000309	CcSEcCtD
Pramipexole—Shock—Betamethasone—multiple sclerosis	0.000116	0.000309	CcSEcCtD
Pramipexole—Dyspnoea—Triamcinolone—multiple sclerosis	0.000116	0.000308	CcSEcCtD
Pramipexole—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000115	0.000308	CcSEcCtD
Pramipexole—Nervous system disorder—Betamethasone—multiple sclerosis	0.000115	0.000308	CcSEcCtD
Pramipexole—Agitation—Prednisone—multiple sclerosis	0.000115	0.000308	CcSEcCtD
Pramipexole—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000115	0.000307	CcSEcCtD
Pramipexole—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000115	0.000307	CcSEcCtD
Pramipexole—Tachycardia—Dexamethasone—multiple sclerosis	0.000115	0.000306	CcSEcCtD
Pramipexole—Tachycardia—Betamethasone—multiple sclerosis	0.000115	0.000306	CcSEcCtD
Pramipexole—Dyspepsia—Triamcinolone—multiple sclerosis	0.000114	0.000305	CcSEcCtD
Pramipexole—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000114	0.000304	CcSEcCtD
Pramipexole—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000114	0.000304	CcSEcCtD
Pramipexole—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000114	0.000304	CcSEcCtD
Pramipexole—Malaise—Prednisone—multiple sclerosis	0.000113	0.000302	CcSEcCtD
Pramipexole—Vertigo—Prednisone—multiple sclerosis	0.000113	0.000301	CcSEcCtD
Pramipexole—Eye disorder—Methotrexate—multiple sclerosis	0.000113	0.000301	CcSEcCtD
Pramipexole—Syncope—Prednisone—multiple sclerosis	0.000113	0.0003	CcSEcCtD
Pramipexole—Tinnitus—Methotrexate—multiple sclerosis	0.000112	0.0003	CcSEcCtD
Pramipexole—Anorexia—Betamethasone—multiple sclerosis	0.000112	0.000299	CcSEcCtD
Pramipexole—Anorexia—Dexamethasone—multiple sclerosis	0.000112	0.000299	CcSEcCtD
Pramipexole—Urticaria—Prednisolone—multiple sclerosis	0.000112	0.000299	CcSEcCtD
Pramipexole—Cardiac disorder—Methotrexate—multiple sclerosis	0.000112	0.000298	CcSEcCtD
Pramipexole—Fatigue—Triamcinolone—multiple sclerosis	0.000112	0.000298	CcSEcCtD
Pramipexole—Fatigue—Methylprednisolone—multiple sclerosis	0.000112	0.000298	CcSEcCtD
Pramipexole—Pain—Triamcinolone—multiple sclerosis	0.000111	0.000296	CcSEcCtD
Pramipexole—Loss of consciousness—Prednisone—multiple sclerosis	0.00011	0.000294	CcSEcCtD
Pramipexole—Hypotension—Betamethasone—multiple sclerosis	0.00011	0.000293	CcSEcCtD
Pramipexole—Hypotension—Dexamethasone—multiple sclerosis	0.00011	0.000293	CcSEcCtD
Pramipexole—Angiopathy—Methotrexate—multiple sclerosis	0.000109	0.000292	CcSEcCtD
Pramipexole—Vomiting—Mitoxantrone—multiple sclerosis	0.000109	0.000292	CcSEcCtD
Pramipexole—Immune system disorder—Methotrexate—multiple sclerosis	0.000109	0.000291	CcSEcCtD
Pramipexole—Convulsion—Prednisone—multiple sclerosis	0.000109	0.00029	CcSEcCtD
Pramipexole—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000109	0.00029	CcSEcCtD
Pramipexole—Hypertension—Prednisone—multiple sclerosis	0.000108	0.000289	CcSEcCtD
Pramipexole—Rash—Mitoxantrone—multiple sclerosis	0.000108	0.000289	CcSEcCtD
Pramipexole—Dermatitis—Mitoxantrone—multiple sclerosis	0.000108	0.000289	CcSEcCtD
Pramipexole—Chills—Methotrexate—multiple sclerosis	0.000108	0.000289	CcSEcCtD
Pramipexole—Headache—Mitoxantrone—multiple sclerosis	0.000108	0.000287	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000107	0.000286	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000107	0.000286	CcSEcCtD
Pramipexole—Myalgia—Prednisone—multiple sclerosis	0.000107	0.000285	CcSEcCtD
Pramipexole—Arthralgia—Prednisone—multiple sclerosis	0.000107	0.000285	CcSEcCtD
Pramipexole—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000107	0.000285	CcSEcCtD
Pramipexole—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000107	0.000285	CcSEcCtD
Pramipexole—Anxiety—Prednisone—multiple sclerosis	0.000107	0.000284	CcSEcCtD
Pramipexole—Alopecia—Methotrexate—multiple sclerosis	0.000107	0.000284	CcSEcCtD
Pramipexole—Insomnia—Dexamethasone—multiple sclerosis	0.000107	0.000284	CcSEcCtD
Pramipexole—Insomnia—Betamethasone—multiple sclerosis	0.000107	0.000284	CcSEcCtD
Pramipexole—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000106	0.000283	CcSEcCtD
Pramipexole—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000106	0.000282	CcSEcCtD
Pramipexole—Paraesthesia—Betamethasone—multiple sclerosis	0.000106	0.000282	CcSEcCtD
Pramipexole—Paraesthesia—Dexamethasone—multiple sclerosis	0.000106	0.000282	CcSEcCtD
Pramipexole—Discomfort—Prednisone—multiple sclerosis	0.000106	0.000282	CcSEcCtD
Pramipexole—Mental disorder—Methotrexate—multiple sclerosis	0.000106	0.000282	CcSEcCtD
Pramipexole—Erythema—Methotrexate—multiple sclerosis	0.000105	0.00028	CcSEcCtD
Pramipexole—Malnutrition—Methotrexate—multiple sclerosis	0.000105	0.00028	CcSEcCtD
Pramipexole—Hypersensitivity—Prednisolone—multiple sclerosis	0.000104	0.000277	CcSEcCtD
Pramipexole—Dyspepsia—Betamethasone—multiple sclerosis	0.000104	0.000276	CcSEcCtD
Pramipexole—Dyspepsia—Dexamethasone—multiple sclerosis	0.000104	0.000276	CcSEcCtD
Pramipexole—Urticaria—Triamcinolone—multiple sclerosis	0.000103	0.000275	CcSEcCtD
Pramipexole—Urticaria—Methylprednisolone—multiple sclerosis	0.000103	0.000274	CcSEcCtD
Pramipexole—Dysgeusia—Methotrexate—multiple sclerosis	0.000103	0.000274	CcSEcCtD
Pramipexole—Body temperature increased—Triamcinolone—multiple sclerosis	0.000103	0.000274	CcSEcCtD
Pramipexole—Oedema—Prednisone—multiple sclerosis	0.000103	0.000273	CcSEcCtD
Pramipexole—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000102	0.000273	CcSEcCtD
Pramipexole—Decreased appetite—Dexamethasone—multiple sclerosis	0.000102	0.000273	CcSEcCtD
Pramipexole—Decreased appetite—Betamethasone—multiple sclerosis	0.000102	0.000273	CcSEcCtD
Pramipexole—Nausea—Mitoxantrone—multiple sclerosis	0.000102	0.000272	CcSEcCtD
Pramipexole—Infection—Prednisone—multiple sclerosis	0.000102	0.000272	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000102	0.000271	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000102	0.000271	CcSEcCtD
Pramipexole—Back pain—Methotrexate—multiple sclerosis	0.000102	0.000271	CcSEcCtD
Pramipexole—Fatigue—Betamethasone—multiple sclerosis	0.000102	0.000271	CcSEcCtD
Pramipexole—Fatigue—Dexamethasone—multiple sclerosis	0.000102	0.000271	CcSEcCtD
Pramipexole—Shock—Prednisone—multiple sclerosis	0.000101	0.000269	CcSEcCtD
Pramipexole—Pain—Betamethasone—multiple sclerosis	0.000101	0.000268	CcSEcCtD
Pramipexole—Pain—Dexamethasone—multiple sclerosis	0.000101	0.000268	CcSEcCtD
Pramipexole—Nervous system disorder—Prednisone—multiple sclerosis	0.000101	0.000268	CcSEcCtD
Pramipexole—Tachycardia—Prednisone—multiple sclerosis	0.0001	0.000267	CcSEcCtD
Pramipexole—Skin disorder—Prednisone—multiple sclerosis	9.96e-05	0.000266	CcSEcCtD
Pramipexole—Hyperhidrosis—Prednisone—multiple sclerosis	9.91e-05	0.000264	CcSEcCtD
Pramipexole—Vision blurred—Methotrexate—multiple sclerosis	9.9e-05	0.000264	CcSEcCtD
Pramipexole—Anorexia—Prednisone—multiple sclerosis	9.78e-05	0.000261	CcSEcCtD
Pramipexole—Ill-defined disorder—Methotrexate—multiple sclerosis	9.74e-05	0.00026	CcSEcCtD
Pramipexole—Anaemia—Methotrexate—multiple sclerosis	9.71e-05	0.000259	CcSEcCtD
Pramipexole—Feeling abnormal—Dexamethasone—multiple sclerosis	9.7e-05	0.000259	CcSEcCtD
Pramipexole—Feeling abnormal—Betamethasone—multiple sclerosis	9.7e-05	0.000259	CcSEcCtD
Pramipexole—Gastrointestinal pain—Betamethasone—multiple sclerosis	9.63e-05	0.000257	CcSEcCtD
Pramipexole—Gastrointestinal pain—Dexamethasone—multiple sclerosis	9.63e-05	0.000257	CcSEcCtD
Pramipexole—Hypersensitivity—Triamcinolone—multiple sclerosis	9.56e-05	0.000255	CcSEcCtD
Pramipexole—Hypersensitivity—Methylprednisolone—multiple sclerosis	9.54e-05	0.000254	CcSEcCtD
Pramipexole—Malaise—Methotrexate—multiple sclerosis	9.47e-05	0.000252	CcSEcCtD
Pramipexole—Vertigo—Methotrexate—multiple sclerosis	9.44e-05	0.000252	CcSEcCtD
Pramipexole—Leukopenia—Methotrexate—multiple sclerosis	9.4e-05	0.000251	CcSEcCtD
Pramipexole—Urticaria—Betamethasone—multiple sclerosis	9.36e-05	0.000249	CcSEcCtD
Pramipexole—Urticaria—Dexamethasone—multiple sclerosis	9.36e-05	0.000249	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Prednisone—multiple sclerosis	9.34e-05	0.000249	CcSEcCtD
Pramipexole—Dizziness—Prednisolone—multiple sclerosis	9.33e-05	0.000249	CcSEcCtD
Pramipexole—Asthenia—Triamcinolone—multiple sclerosis	9.31e-05	0.000248	CcSEcCtD
Pramipexole—Abdominal pain—Betamethasone—multiple sclerosis	9.31e-05	0.000248	CcSEcCtD
Pramipexole—Abdominal pain—Dexamethasone—multiple sclerosis	9.31e-05	0.000248	CcSEcCtD
Pramipexole—Body temperature increased—Betamethasone—multiple sclerosis	9.31e-05	0.000248	CcSEcCtD
Pramipexole—Body temperature increased—Dexamethasone—multiple sclerosis	9.31e-05	0.000248	CcSEcCtD
Pramipexole—Asthenia—Methylprednisolone—multiple sclerosis	9.29e-05	0.000248	CcSEcCtD
Pramipexole—Insomnia—Prednisone—multiple sclerosis	9.28e-05	0.000247	CcSEcCtD
Pramipexole—Paraesthesia—Prednisone—multiple sclerosis	9.21e-05	0.000246	CcSEcCtD
Pramipexole—Pruritus—Triamcinolone—multiple sclerosis	9.18e-05	0.000245	CcSEcCtD
Pramipexole—Cough—Methotrexate—multiple sclerosis	9.16e-05	0.000244	CcSEcCtD
Pramipexole—Pruritus—Methylprednisolone—multiple sclerosis	9.16e-05	0.000244	CcSEcCtD
Pramipexole—Convulsion—Methotrexate—multiple sclerosis	9.1e-05	0.000243	CcSEcCtD
Pramipexole—Dyspepsia—Prednisone—multiple sclerosis	9.03e-05	0.000241	CcSEcCtD
Pramipexole—Myalgia—Methotrexate—multiple sclerosis	8.94e-05	0.000238	CcSEcCtD
Pramipexole—Chest pain—Methotrexate—multiple sclerosis	8.94e-05	0.000238	CcSEcCtD
Pramipexole—Arthralgia—Methotrexate—multiple sclerosis	8.94e-05	0.000238	CcSEcCtD
Pramipexole—Decreased appetite—Prednisone—multiple sclerosis	8.91e-05	0.000238	CcSEcCtD
Pramipexole—Rash—Prednisolone—multiple sclerosis	8.9e-05	0.000237	CcSEcCtD
Pramipexole—Dermatitis—Prednisolone—multiple sclerosis	8.89e-05	0.000237	CcSEcCtD
Pramipexole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	8.88e-05	0.000237	CcSEcCtD
Pramipexole—Diarrhoea—Methylprednisolone—multiple sclerosis	8.86e-05	0.000236	CcSEcCtD
Pramipexole—Fatigue—Prednisone—multiple sclerosis	8.84e-05	0.000236	CcSEcCtD
Pramipexole—Headache—Prednisolone—multiple sclerosis	8.84e-05	0.000236	CcSEcCtD
Pramipexole—Discomfort—Methotrexate—multiple sclerosis	8.83e-05	0.000236	CcSEcCtD
Pramipexole—Constipation—Prednisone—multiple sclerosis	8.77e-05	0.000234	CcSEcCtD
Pramipexole—Confusional state—Methotrexate—multiple sclerosis	8.64e-05	0.00023	CcSEcCtD
Pramipexole—Dizziness—Triamcinolone—multiple sclerosis	8.58e-05	0.000229	CcSEcCtD
Pramipexole—Dizziness—Methylprednisolone—multiple sclerosis	8.56e-05	0.000228	CcSEcCtD
Pramipexole—Infection—Methotrexate—multiple sclerosis	8.51e-05	0.000227	CcSEcCtD
Pramipexole—Feeling abnormal—Prednisone—multiple sclerosis	8.45e-05	0.000225	CcSEcCtD
Pramipexole—Asthenia—Betamethasone—multiple sclerosis	8.45e-05	0.000225	CcSEcCtD
Pramipexole—Asthenia—Dexamethasone—multiple sclerosis	8.45e-05	0.000225	CcSEcCtD
Pramipexole—Nervous system disorder—Methotrexate—multiple sclerosis	8.41e-05	0.000224	CcSEcCtD
Pramipexole—Thrombocytopenia—Methotrexate—multiple sclerosis	8.39e-05	0.000224	CcSEcCtD
Pramipexole—Gastrointestinal pain—Prednisone—multiple sclerosis	8.39e-05	0.000224	CcSEcCtD
Pramipexole—Nausea—Prednisolone—multiple sclerosis	8.38e-05	0.000223	CcSEcCtD
Pramipexole—Pruritus—Dexamethasone—multiple sclerosis	8.33e-05	0.000222	CcSEcCtD
Pramipexole—Pruritus—Betamethasone—multiple sclerosis	8.33e-05	0.000222	CcSEcCtD
Pramipexole—Skin disorder—Methotrexate—multiple sclerosis	8.32e-05	0.000222	CcSEcCtD
Pramipexole—Hyperhidrosis—Methotrexate—multiple sclerosis	8.29e-05	0.000221	CcSEcCtD
Pramipexole—Vomiting—Triamcinolone—multiple sclerosis	8.25e-05	0.00022	CcSEcCtD
Pramipexole—Vomiting—Methylprednisolone—multiple sclerosis	8.23e-05	0.00022	CcSEcCtD
Pramipexole—Rash—Triamcinolone—multiple sclerosis	8.18e-05	0.000218	CcSEcCtD
Pramipexole—Dermatitis—Triamcinolone—multiple sclerosis	8.18e-05	0.000218	CcSEcCtD
Pramipexole—Anorexia—Methotrexate—multiple sclerosis	8.17e-05	0.000218	CcSEcCtD
Pramipexole—Rash—Methylprednisolone—multiple sclerosis	8.16e-05	0.000218	CcSEcCtD
Pramipexole—Dermatitis—Methylprednisolone—multiple sclerosis	8.16e-05	0.000217	CcSEcCtD
Pramipexole—Urticaria—Prednisone—multiple sclerosis	8.15e-05	0.000217	CcSEcCtD
Pramipexole—Headache—Triamcinolone—multiple sclerosis	8.13e-05	0.000217	CcSEcCtD
Pramipexole—Headache—Methylprednisolone—multiple sclerosis	8.11e-05	0.000216	CcSEcCtD
Pramipexole—Abdominal pain—Prednisone—multiple sclerosis	8.11e-05	0.000216	CcSEcCtD
Pramipexole—Body temperature increased—Prednisone—multiple sclerosis	8.11e-05	0.000216	CcSEcCtD
Pramipexole—Diarrhoea—Dexamethasone—multiple sclerosis	8.06e-05	0.000215	CcSEcCtD
Pramipexole—Diarrhoea—Betamethasone—multiple sclerosis	8.06e-05	0.000215	CcSEcCtD
Pramipexole—Hypotension—Methotrexate—multiple sclerosis	8.01e-05	0.000214	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	7.81e-05	0.000208	CcSEcCtD
Pramipexole—Dizziness—Dexamethasone—multiple sclerosis	7.79e-05	0.000208	CcSEcCtD
Pramipexole—Dizziness—Betamethasone—multiple sclerosis	7.79e-05	0.000208	CcSEcCtD
Pramipexole—Insomnia—Methotrexate—multiple sclerosis	7.75e-05	0.000207	CcSEcCtD
Pramipexole—Nausea—Triamcinolone—multiple sclerosis	7.71e-05	0.000206	CcSEcCtD
Pramipexole—Paraesthesia—Methotrexate—multiple sclerosis	7.7e-05	0.000205	CcSEcCtD
Pramipexole—Nausea—Methylprednisolone—multiple sclerosis	7.69e-05	0.000205	CcSEcCtD
Pramipexole—Dyspnoea—Methotrexate—multiple sclerosis	7.64e-05	0.000204	CcSEcCtD
Pramipexole—Somnolence—Methotrexate—multiple sclerosis	7.62e-05	0.000203	CcSEcCtD
Pramipexole—Hypersensitivity—Prednisone—multiple sclerosis	7.56e-05	0.000201	CcSEcCtD
Pramipexole—Dyspepsia—Methotrexate—multiple sclerosis	7.54e-05	0.000201	CcSEcCtD
Pramipexole—Vomiting—Dexamethasone—multiple sclerosis	7.49e-05	0.0002	CcSEcCtD
Pramipexole—Vomiting—Betamethasone—multiple sclerosis	7.49e-05	0.0002	CcSEcCtD
Pramipexole—Decreased appetite—Methotrexate—multiple sclerosis	7.45e-05	0.000199	CcSEcCtD
Pramipexole—Rash—Betamethasone—multiple sclerosis	7.42e-05	0.000198	CcSEcCtD
Pramipexole—Rash—Dexamethasone—multiple sclerosis	7.42e-05	0.000198	CcSEcCtD
Pramipexole—Dermatitis—Dexamethasone—multiple sclerosis	7.42e-05	0.000198	CcSEcCtD
Pramipexole—Dermatitis—Betamethasone—multiple sclerosis	7.42e-05	0.000198	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Methotrexate—multiple sclerosis	7.4e-05	0.000197	CcSEcCtD
Pramipexole—Fatigue—Methotrexate—multiple sclerosis	7.39e-05	0.000197	CcSEcCtD
Pramipexole—Headache—Betamethasone—multiple sclerosis	7.38e-05	0.000197	CcSEcCtD
Pramipexole—Headache—Dexamethasone—multiple sclerosis	7.38e-05	0.000197	CcSEcCtD
Pramipexole—Asthenia—Prednisone—multiple sclerosis	7.36e-05	0.000196	CcSEcCtD
Pramipexole—Pain—Methotrexate—multiple sclerosis	7.33e-05	0.000195	CcSEcCtD
Pramipexole—Pruritus—Prednisone—multiple sclerosis	7.26e-05	0.000193	CcSEcCtD
Pramipexole—Feeling abnormal—Methotrexate—multiple sclerosis	7.06e-05	0.000188	CcSEcCtD
Pramipexole—Diarrhoea—Prednisone—multiple sclerosis	7.02e-05	0.000187	CcSEcCtD
Pramipexole—Gastrointestinal pain—Methotrexate—multiple sclerosis	7.01e-05	0.000187	CcSEcCtD
Pramipexole—Nausea—Betamethasone—multiple sclerosis	6.99e-05	0.000186	CcSEcCtD
Pramipexole—Nausea—Dexamethasone—multiple sclerosis	6.99e-05	0.000186	CcSEcCtD
Pramipexole—Urticaria—Methotrexate—multiple sclerosis	6.81e-05	0.000182	CcSEcCtD
Pramipexole—Dizziness—Prednisone—multiple sclerosis	6.78e-05	0.000181	CcSEcCtD
Pramipexole—Abdominal pain—Methotrexate—multiple sclerosis	6.78e-05	0.000181	CcSEcCtD
Pramipexole—Body temperature increased—Methotrexate—multiple sclerosis	6.78e-05	0.000181	CcSEcCtD
Pramipexole—Vomiting—Prednisone—multiple sclerosis	6.52e-05	0.000174	CcSEcCtD
Pramipexole—Rash—Prednisone—multiple sclerosis	6.47e-05	0.000172	CcSEcCtD
Pramipexole—Dermatitis—Prednisone—multiple sclerosis	6.46e-05	0.000172	CcSEcCtD
Pramipexole—Headache—Prednisone—multiple sclerosis	6.42e-05	0.000171	CcSEcCtD
Pramipexole—Hypersensitivity—Methotrexate—multiple sclerosis	6.31e-05	0.000168	CcSEcCtD
Pramipexole—Asthenia—Methotrexate—multiple sclerosis	6.15e-05	0.000164	CcSEcCtD
Pramipexole—Nausea—Prednisone—multiple sclerosis	6.09e-05	0.000162	CcSEcCtD
Pramipexole—Pruritus—Methotrexate—multiple sclerosis	6.06e-05	0.000162	CcSEcCtD
Pramipexole—Diarrhoea—Methotrexate—multiple sclerosis	5.86e-05	0.000156	CcSEcCtD
Pramipexole—Dizziness—Methotrexate—multiple sclerosis	5.67e-05	0.000151	CcSEcCtD
Pramipexole—Vomiting—Methotrexate—multiple sclerosis	5.45e-05	0.000145	CcSEcCtD
Pramipexole—Rash—Methotrexate—multiple sclerosis	5.4e-05	0.000144	CcSEcCtD
Pramipexole—Dermatitis—Methotrexate—multiple sclerosis	5.4e-05	0.000144	CcSEcCtD
Pramipexole—Headache—Methotrexate—multiple sclerosis	5.37e-05	0.000143	CcSEcCtD
Pramipexole—Nausea—Methotrexate—multiple sclerosis	5.09e-05	0.000136	CcSEcCtD
Pramipexole—HTR1A—Signaling Pathways—CCL5—multiple sclerosis	1.76e-05	0.000123	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CCL5—multiple sclerosis	1.75e-05	0.000122	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—CD80—multiple sclerosis	1.75e-05	0.000122	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CD86—multiple sclerosis	1.73e-05	0.000121	CbGpPWpGaD
Pramipexole—SLC22A2—Metabolism—APOE—multiple sclerosis	1.72e-05	0.00012	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—CD80—multiple sclerosis	1.71e-05	0.00012	CbGpPWpGaD
Pramipexole—HTR1A—GPCR downstream signaling—IL2—multiple sclerosis	1.71e-05	0.000119	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CCL5—multiple sclerosis	1.7e-05	0.000119	CbGpPWpGaD
Pramipexole—HTR2C—GPCR downstream signaling—IL2—multiple sclerosis	1.7e-05	0.000119	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—SPP1—multiple sclerosis	1.69e-05	0.000118	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—CD80—multiple sclerosis	1.69e-05	0.000118	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—APOE—multiple sclerosis	1.68e-05	0.000117	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—APOE—multiple sclerosis	1.67e-05	0.000117	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—POMC—multiple sclerosis	1.66e-05	0.000116	CbGpPWpGaD
Pramipexole—ADRA2A—Hemostasis—TGFB1—multiple sclerosis	1.66e-05	0.000116	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—APOE—multiple sclerosis	1.66e-05	0.000116	CbGpPWpGaD
Pramipexole—ADRA2C—GPCR downstream signaling—IL2—multiple sclerosis	1.65e-05	0.000115	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—POMC—multiple sclerosis	1.65e-05	0.000115	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—CCR5—multiple sclerosis	1.64e-05	0.000115	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—TYK2—multiple sclerosis	1.64e-05	0.000114	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—SPP1—multiple sclerosis	1.63e-05	0.000114	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—POMC—multiple sclerosis	1.63e-05	0.000114	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—CCL2—multiple sclerosis	1.63e-05	0.000114	CbGpPWpGaD
Pramipexole—ADRA2A—Hemostasis—MAPK1—multiple sclerosis	1.63e-05	0.000113	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—SPP1—multiple sclerosis	1.62e-05	0.000113	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—IL2RA—multiple sclerosis	1.62e-05	0.000113	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—CCL2—multiple sclerosis	1.61e-05	0.000113	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—TYK2—multiple sclerosis	1.61e-05	0.000112	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—CD80—multiple sclerosis	1.61e-05	0.000112	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CXCL10—multiple sclerosis	1.61e-05	0.000112	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling by GPCR—IL2—multiple sclerosis	1.61e-05	0.000112	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—IL2—multiple sclerosis	1.6e-05	0.000112	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—POMC—multiple sclerosis	1.6e-05	0.000112	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—APOE—multiple sclerosis	1.6e-05	0.000112	CbGpPWpGaD
Pramipexole—DRD5—Signaling by GPCR—IL6—multiple sclerosis	1.6e-05	0.000111	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—CCL2—multiple sclerosis	1.59e-05	0.000111	CbGpPWpGaD
Pramipexole—HTR1D—Signaling by GPCR—MAPK1—multiple sclerosis	1.59e-05	0.000111	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CCR5—multiple sclerosis	1.59e-05	0.000111	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CCR5—multiple sclerosis	1.58e-05	0.00011	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—SPP1—multiple sclerosis	1.58e-05	0.00011	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CD86—multiple sclerosis	1.57e-05	0.00011	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—CCL2—multiple sclerosis	1.57e-05	0.000109	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—IL2RA—multiple sclerosis	1.56e-05	0.000109	CbGpPWpGaD
Pramipexole—HTR1B—Signaling by GPCR—MAPK1—multiple sclerosis	1.56e-05	0.000109	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—IL2RA—multiple sclerosis	1.56e-05	0.000109	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—IL2—multiple sclerosis	1.55e-05	0.000108	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CCL5—multiple sclerosis	1.55e-05	0.000108	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CD86—multiple sclerosis	1.55e-05	0.000108	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—IL2—multiple sclerosis	1.54e-05	0.000108	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CCR5—multiple sclerosis	1.54e-05	0.000107	CbGpPWpGaD
Pramipexole—DRD4—Signaling by GPCR—MAPK1—multiple sclerosis	1.53e-05	0.000107	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—POMC—multiple sclerosis	1.53e-05	0.000107	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CCL5—multiple sclerosis	1.52e-05	0.000106	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—MMP9—multiple sclerosis	1.52e-05	0.000106	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—CD80—multiple sclerosis	1.52e-05	0.000106	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—IL2RA—multiple sclerosis	1.51e-05	0.000106	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—IL2—multiple sclerosis	1.5e-05	0.000105	CbGpPWpGaD
Pramipexole—DRD2—GPCR downstream signaling—IL2—multiple sclerosis	1.5e-05	0.000105	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—CD80—multiple sclerosis	1.5e-05	0.000104	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—CCL2—multiple sclerosis	1.5e-05	0.000104	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—APOE—multiple sclerosis	1.5e-05	0.000104	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—TYK2—multiple sclerosis	1.48e-05	0.000103	CbGpPWpGaD
Pramipexole—HTR2A—GPCR downstream signaling—IL2—multiple sclerosis	1.48e-05	0.000103	CbGpPWpGaD
Pramipexole—SLC22A2—Metabolism—POMC—multiple sclerosis	1.48e-05	0.000103	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—TYK2—multiple sclerosis	1.47e-05	0.000102	CbGpPWpGaD
Pramipexole—HTR2B—Signaling by GPCR—MAPK1—multiple sclerosis	1.46e-05	0.000102	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—TYK2—multiple sclerosis	1.45e-05	0.000101	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—APOE—multiple sclerosis	1.44e-05	0.000101	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—POMC—multiple sclerosis	1.44e-05	0.000101	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—APOE—multiple sclerosis	1.44e-05	0.0001	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—POMC—multiple sclerosis	1.43e-05	0.0001	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—SPP1—multiple sclerosis	1.43e-05	9.99e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—TYK2—multiple sclerosis	1.42e-05	9.93e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—POMC—multiple sclerosis	1.42e-05	9.93e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—CCL2—multiple sclerosis	1.41e-05	9.85e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—SPP1—multiple sclerosis	1.41e-05	9.83e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CD86—multiple sclerosis	1.41e-05	9.81e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—APOE—multiple sclerosis	1.4e-05	9.75e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CCR5—multiple sclerosis	1.39e-05	9.72e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—CCL2—multiple sclerosis	1.39e-05	9.71e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CCL5—multiple sclerosis	1.38e-05	9.66e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling by GPCR—MAPK1—multiple sclerosis	1.38e-05	9.63e-05	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—POMC—multiple sclerosis	1.38e-05	9.6e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—IL2RA—multiple sclerosis	1.37e-05	9.58e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CCR5—multiple sclerosis	1.37e-05	9.56e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—IL2—multiple sclerosis	1.36e-05	9.51e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling by GPCR—MAPK1—multiple sclerosis	1.36e-05	9.5e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—TYK2—multiple sclerosis	1.36e-05	9.48e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—APOE—multiple sclerosis	1.36e-05	9.47e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—CD80—multiple sclerosis	1.35e-05	9.43e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—IL2RA—multiple sclerosis	1.35e-05	9.43e-05	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—STAT3—multiple sclerosis	1.35e-05	9.42e-05	CbGpPWpGaD
Pramipexole—SLC22A2—Metabolism—ALB—multiple sclerosis	1.34e-05	9.39e-05	CbGpPWpGaD
Pramipexole—ADRA2A—GPCR downstream signaling—IL2—multiple sclerosis	1.34e-05	9.37e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—IL2—multiple sclerosis	1.34e-05	9.35e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—ALB—multiple sclerosis	1.31e-05	9.13e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CD80—multiple sclerosis	1.3e-05	9.11e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CD80—multiple sclerosis	1.3e-05	9.06e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—POMC—multiple sclerosis	1.28e-05	8.96e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—SPP1—multiple sclerosis	1.28e-05	8.95e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—TYK2—multiple sclerosis	1.28e-05	8.94e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—APOE—multiple sclerosis	1.27e-05	8.84e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—TYK2—multiple sclerosis	1.26e-05	8.82e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CD80—multiple sclerosis	1.26e-05	8.81e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—CCL2—multiple sclerosis	1.26e-05	8.77e-05	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—MYC—multiple sclerosis	1.25e-05	8.75e-05	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—ALB—multiple sclerosis	1.25e-05	8.75e-05	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—TGFB1—multiple sclerosis	1.25e-05	8.73e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—APOE—multiple sclerosis	1.25e-05	8.7e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CCR5—multiple sclerosis	1.25e-05	8.7e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—POMC—multiple sclerosis	1.24e-05	8.65e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—POMC—multiple sclerosis	1.23e-05	8.61e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling by GPCR—MAPK1—multiple sclerosis	1.23e-05	8.58e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—IL2—multiple sclerosis	1.23e-05	8.58e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—IL2RA—multiple sclerosis	1.23e-05	8.58e-05	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—MAPK1—multiple sclerosis	1.23e-05	8.56e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling by GPCR—IL6—multiple sclerosis	1.22e-05	8.53e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—IL2—multiple sclerosis	1.22e-05	8.51e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CCL2—multiple sclerosis	1.21e-05	8.47e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CCL2—multiple sclerosis	1.21e-05	8.42e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—IL2—multiple sclerosis	1.2e-05	8.4e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—POMC—multiple sclerosis	1.2e-05	8.37e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling by GPCR—IL6—multiple sclerosis	1.2e-05	8.36e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—MAPK1—multiple sclerosis	1.19e-05	8.28e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—IL2—multiple sclerosis	1.18e-05	8.26e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—MAPK1—multiple sclerosis	1.18e-05	8.24e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling by GPCR—IL6—multiple sclerosis	1.18e-05	8.22e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CCL2—multiple sclerosis	1.17e-05	8.19e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—POMC—multiple sclerosis	1.17e-05	8.13e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—MMP9—multiple sclerosis	1.16e-05	8.12e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—MAPK1—multiple sclerosis	1.15e-05	8.02e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CD80—multiple sclerosis	1.15e-05	8e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—TYK2—multiple sclerosis	1.14e-05	7.96e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—MMP9—multiple sclerosis	1.14e-05	7.95e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—APOE—multiple sclerosis	1.13e-05	7.92e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—IL2—multiple sclerosis	1.13e-05	7.89e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CD80—multiple sclerosis	1.13e-05	7.87e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling by GPCR—IL6—multiple sclerosis	1.12e-05	7.85e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—MMP9—multiple sclerosis	1.12e-05	7.82e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—TYK2—multiple sclerosis	1.1e-05	7.69e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—TYK2—multiple sclerosis	1.1e-05	7.65e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—POMC—multiple sclerosis	1.09e-05	7.6e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—POMC—multiple sclerosis	1.07e-05	7.48e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—MMP9—multiple sclerosis	1.07e-05	7.47e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—TYK2—multiple sclerosis	1.07e-05	7.44e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—IL2—multiple sclerosis	1.07e-05	7.44e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CCL2—multiple sclerosis	1.07e-05	7.43e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—ALB—multiple sclerosis	1.06e-05	7.42e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling by GPCR—IL6—multiple sclerosis	1.06e-05	7.4e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—IL2—multiple sclerosis	1.05e-05	7.34e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CCL2—multiple sclerosis	1.05e-05	7.31e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling by GPCR—IL6—multiple sclerosis	1.05e-05	7.3e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—MAPK1—multiple sclerosis	1.04e-05	7.27e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—STAT3—multiple sclerosis	1.03e-05	7.22e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CD80—multiple sclerosis	1.03e-05	7.16e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—MAPK1—multiple sclerosis	1.03e-05	7.16e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—STAT3—multiple sclerosis	1.01e-05	7.07e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—MMP9—multiple sclerosis	1.01e-05	7.04e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—STAT3—multiple sclerosis	9.96e-06	6.95e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—MMP9—multiple sclerosis	9.95e-06	6.95e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—POMC—multiple sclerosis	9.75e-06	6.8e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—TYK2—multiple sclerosis	9.67e-06	6.75e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—MYC—multiple sclerosis	9.61e-06	6.71e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—TGFB1—multiple sclerosis	9.59e-06	6.69e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CCL2—multiple sclerosis	9.54e-06	6.65e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—TYK2—multiple sclerosis	9.52e-06	6.64e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—STAT3—multiple sclerosis	9.51e-06	6.64e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—IL2—multiple sclerosis	9.5e-06	6.63e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling by GPCR—IL6—multiple sclerosis	9.45e-06	6.59e-05	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—IL6—multiple sclerosis	9.43e-06	6.58e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—MYC—multiple sclerosis	9.41e-06	6.57e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—MAPK1—multiple sclerosis	9.4e-06	6.56e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—TGFB1—multiple sclerosis	9.39e-06	6.55e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—MAPK1—multiple sclerosis	9.33e-06	6.51e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—MYC—multiple sclerosis	9.26e-06	6.46e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—TGFB1—multiple sclerosis	9.24e-06	6.45e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—MAPK1—multiple sclerosis	9.2e-06	6.42e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—IL2—multiple sclerosis	9.17e-06	6.4e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—IL6—multiple sclerosis	9.12e-06	6.36e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—IL2—multiple sclerosis	9.12e-06	6.36e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—IL6—multiple sclerosis	9.07e-06	6.33e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—MAPK1—multiple sclerosis	9.06e-06	6.32e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—MMP9—multiple sclerosis	8.99e-06	6.27e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—STAT3—multiple sclerosis	8.97e-06	6.26e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—IL2—multiple sclerosis	8.87e-06	6.19e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—STAT3—multiple sclerosis	8.85e-06	6.18e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—MYC—multiple sclerosis	8.84e-06	6.17e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—IL6—multiple sclerosis	8.83e-06	6.16e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—TGFB1—multiple sclerosis	8.82e-06	6.15e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—MMP9—multiple sclerosis	8.68e-06	6.05e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—TYK2—multiple sclerosis	8.66e-06	6.04e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—MAPK1—multiple sclerosis	8.65e-06	6.03e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—MMP9—multiple sclerosis	8.63e-06	6.02e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—MMP9—multiple sclerosis	8.39e-06	5.86e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—MYC—multiple sclerosis	8.34e-06	5.82e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—TGFB1—multiple sclerosis	8.31e-06	5.8e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—MYC—multiple sclerosis	8.22e-06	5.74e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—TGFB1—multiple sclerosis	8.2e-06	5.73e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—MAPK1—multiple sclerosis	8.15e-06	5.69e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—IL2—multiple sclerosis	8.05e-06	5.62e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—MAPK1—multiple sclerosis	8.05e-06	5.61e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—IL6—multiple sclerosis	8.01e-06	5.59e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—STAT3—multiple sclerosis	7.99e-06	5.58e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—IL2—multiple sclerosis	7.92e-06	5.53e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—IL6—multiple sclerosis	7.88e-06	5.5e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—STAT3—multiple sclerosis	7.71e-06	5.38e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—STAT3—multiple sclerosis	7.67e-06	5.36e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—MMP9—multiple sclerosis	7.62e-06	5.32e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—MMP9—multiple sclerosis	7.49e-06	5.23e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—STAT3—multiple sclerosis	7.46e-06	5.21e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—MYC—multiple sclerosis	7.42e-06	5.18e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—TGFB1—multiple sclerosis	7.41e-06	5.17e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—MAPK1—multiple sclerosis	7.26e-06	5.07e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—IL6—multiple sclerosis	7.22e-06	5.04e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—IL2—multiple sclerosis	7.2e-06	5.03e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—IL6—multiple sclerosis	7.17e-06	5e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—MYC—multiple sclerosis	7.17e-06	5e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—TGFB1—multiple sclerosis	7.15e-06	4.99e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—MYC—multiple sclerosis	7.13e-06	4.98e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—TGFB1—multiple sclerosis	7.11e-06	4.96e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—IL6—multiple sclerosis	7.07e-06	4.94e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—MAPK1—multiple sclerosis	7.01e-06	4.89e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—MAPK1—multiple sclerosis	6.98e-06	4.87e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—IL6—multiple sclerosis	6.96e-06	4.86e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—MYC—multiple sclerosis	6.94e-06	4.84e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—TGFB1—multiple sclerosis	6.92e-06	4.83e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MMP9—multiple sclerosis	6.82e-06	4.76e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—MAPK1—multiple sclerosis	6.79e-06	4.73e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—STAT3—multiple sclerosis	6.77e-06	4.73e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—STAT3—multiple sclerosis	6.66e-06	4.65e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—IL6—multiple sclerosis	6.64e-06	4.64e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—MYC—multiple sclerosis	6.29e-06	4.39e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—TGFB1—multiple sclerosis	6.28e-06	4.38e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—IL6—multiple sclerosis	6.27e-06	4.37e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—MYC—multiple sclerosis	6.19e-06	4.32e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—IL6—multiple sclerosis	6.18e-06	4.31e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—TGFB1—multiple sclerosis	6.18e-06	4.31e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—MAPK1—multiple sclerosis	6.16e-06	4.3e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—STAT3—multiple sclerosis	6.06e-06	4.23e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—MAPK1—multiple sclerosis	6.06e-06	4.23e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MYC—multiple sclerosis	5.63e-06	3.93e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—TGFB1—multiple sclerosis	5.62e-06	3.92e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—IL6—multiple sclerosis	5.58e-06	3.89e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MAPK1—multiple sclerosis	5.51e-06	3.85e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—IL6—multiple sclerosis	5.39e-06	3.76e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—IL6—multiple sclerosis	5.36e-06	3.74e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—IL6—multiple sclerosis	5.21e-06	3.64e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—IL6—multiple sclerosis	4.73e-06	3.3e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—IL6—multiple sclerosis	4.65e-06	3.25e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—IL6—multiple sclerosis	4.23e-06	2.96e-05	CbGpPWpGaD
